Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Roth

Showing results (371-380 of 396) with videos related to

Pageof 40
Sort By:
Psychological Medicine|May 25, 2018
Efficacy of digital CBT for insomnia to reduce depression across demographic groups: a randomized trialPhilip Cheng, Annemarie I Luik, Cynthia Fellman-Couture, et al.
Frontiers in Sleep|August 31, 2022
A Nationally Representative Survey Assessing Restorative Sleep in US AdultsRebecca Robbins, Stuart F Quan, Daniel Buysse, et al.
Sleep Medicine|August 4, 2012
Impact of paroxetine on sleep problems in 426 cancer patients receiving chemotherapy: a trial from the University of Rochester Cancer Center Community Clinical Oncology ProgramOxana G Palesh, Karen M Mustian, Luke J Peppone, et al.
JAMA Neurology|May 8, 2013
Nocturnal rapid eye movement sleep latency for identifying patients with narcolepsy/hypocretin deficiencyOlivier Andlauer, Hyatt Moore, Laura Jouhier, et al.
Sleep Advances : a Journal of the Sleep Research Society|April 8, 2022
DSM-5 insomnia disorder in pregnancy: associations with depression, suicidal ideation, and cognitive and somatic arousal, and identifying clinical cutoffs for detectionDavid A Kalmbach, Philip Cheng, Andrea Roth, et al.
Journal of Medicinal Chemistry|August 1, 2007
Synthesis, biological activity, and crystal structure of potent nonnucleoside inhibitors of HIV-1 reverse transcriptase that retain activity against mutant forms of the enzymeMarshall L Morningstar, Thomas Roth, David W Farnsworth, et al.
Sleep Advances : a Journal of the Sleep Research Society|August 30, 2023
Reducing cognitive arousal and sleep effort alleviates insomnia and depression in pregnant women with DSM-5 insomnia disorder treated with a mindfulness sleep programDavid A Kalmbach, Philip Cheng, Anthony N Reffi, et al.
The Lancet. Neurology|April 1, 2014
Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trialDavid Michelson, Ellen Snyder, Erin Paradis, et al.
Psychopharmacology|March 8, 2017
Clinical profile of suvorexant for the treatment of insomnia over 3 months in women and men: subgroup analysis of pooled phase-3 dataW Joseph Herring, Kathryn M Connor, Ellen Snyder, et al.
Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy of Sleep Medicine|July 12, 2016
Suvorexant in Patients with Insomnia: Pooled Analyses of Three-Month Data from Phase-3 Randomized Controlled Clinical TrialsW Joseph Herring, Kathleen M Connor, Ellen Snyder, et al.
Pageof 40

Showing results (371-380 of 396) with videos related to

Sort By:
Pageof 40
Psychological Medicine|May 25, 2018
Efficacy of digital CBT for insomnia to reduce depression across demographic groups: a randomized trialPhilip Cheng, Annemarie I Luik, Cynthia Fellman-Couture, et al.
Frontiers in Sleep|August 31, 2022
A Nationally Representative Survey Assessing Restorative Sleep in US AdultsRebecca Robbins, Stuart F Quan, Daniel Buysse, et al.
Sleep Medicine|August 4, 2012
Impact of paroxetine on sleep problems in 426 cancer patients receiving chemotherapy: a trial from the University of Rochester Cancer Center Community Clinical Oncology ProgramOxana G Palesh, Karen M Mustian, Luke J Peppone, et al.
JAMA Neurology|May 8, 2013
Nocturnal rapid eye movement sleep latency for identifying patients with narcolepsy/hypocretin deficiencyOlivier Andlauer, Hyatt Moore, Laura Jouhier, et al.
Sleep Advances : a Journal of the Sleep Research Society|April 8, 2022
DSM-5 insomnia disorder in pregnancy: associations with depression, suicidal ideation, and cognitive and somatic arousal, and identifying clinical cutoffs for detectionDavid A Kalmbach, Philip Cheng, Andrea Roth, et al.
Journal of Medicinal Chemistry|August 1, 2007
Synthesis, biological activity, and crystal structure of potent nonnucleoside inhibitors of HIV-1 reverse transcriptase that retain activity against mutant forms of the enzymeMarshall L Morningstar, Thomas Roth, David W Farnsworth, et al.
Sleep Advances : a Journal of the Sleep Research Society|August 30, 2023
Reducing cognitive arousal and sleep effort alleviates insomnia and depression in pregnant women with DSM-5 insomnia disorder treated with a mindfulness sleep programDavid A Kalmbach, Philip Cheng, Anthony N Reffi, et al.
The Lancet. Neurology|April 1, 2014
Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trialDavid Michelson, Ellen Snyder, Erin Paradis, et al.
Psychopharmacology|March 8, 2017
Clinical profile of suvorexant for the treatment of insomnia over 3 months in women and men: subgroup analysis of pooled phase-3 dataW Joseph Herring, Kathryn M Connor, Ellen Snyder, et al.
Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy of Sleep Medicine|July 12, 2016
Suvorexant in Patients with Insomnia: Pooled Analyses of Three-Month Data from Phase-3 Randomized Controlled Clinical TrialsW Joseph Herring, Kathleen M Connor, Ellen Snyder, et al.
Pageof 40